- Home
- MBRX vs ADXN Comparison
MBRX vs ADXN Comparison
Compare MBRX & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBRX | ADXN |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 8.6M |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MBRX | ADXN |
|---|---|---|
| Price | $6.25 | $2.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 879.9K | 9.2K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $767.75 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $2.56 |
| 52 Week High | $15.75 | $10.43 |
Technical Indicators
Market Signals| Indicator | MBRX | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 94.44 | 44.36 |
| Support Level | $2.12 | $2.56 |
| Resistance Level | N/A | $3.80 |
| Average True Range (ATR) | 0.16 | 0.20 |
| MACD | 0.59 | 0.05 |
| Stochastic Oscillator | 94.57 | 57.34 |
Price Performance
Historical ComparisonAbout MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.